Month: April 2023

The net asset value (NAV) of the Baltic Horizon Fund (the Fund) unit at the end of March 2023 amounted to EUR 1.1156 per unit. Compared to the previous month, NAV per unit increased by 0.1%. The total net asset value of the Fund amounted to EUR 133.5 million over the month. The EPRA NRV as of 31 March 2023 was EUR 1.1668 per unit, corresponding to a decrease of 1.3% over the last month. Unaudited consolidated net rental income for March 2023 amounted to EUR 1.4 million (EUR 1.4 million in February 2023). The net rental income has increased by 3.0% compared to February 2023. 6 March 2023 was the closing date of the Domus Pro share sale transaction, therefore only six days of Domus Pro operating results impact the net rental income of the Fund in March 2023. The Fund recognized an unaudited consolidated net profit of EUR 0.5 million in March...

The net asset value (NAV) of the Baltic Horizon Fund (the Fund) unit at the end of March 2023 amounted to EUR 1.1156 per unit. Compared to the previous month, NAV per unit increased by 0.1%. The total net asset value of the Fund amounted to EUR 133.5 million over the month. The EPRA NRV as of 31 March 2023 was EUR 1.1668 per unit, corresponding to a decrease of 1.3% over the last month. Unaudited consolidated net rental income for March 2023 amounted to EUR 1.4 million (EUR 1.4 million in February 2023). The net rental income has increased by 3.0% compared to February 2023. 6 March 2023 was the closing date of the Domus Pro share sale transaction, therefore only six days of Domus Pro operating results impact the net rental income of the Fund in March 2023. The Fund recognized an unaudited consolidated net profit of EUR 0.5 million in March...

Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse eventsBreadth of responses observed across tumor types and BRAF or NRAS alterations with a total of 8 partial responses in the monotherapy and combination armsMonotherapy dose expansion ongoing at 300 mg bid; data-informed strategy prioritizes enrollment in BRAF Class II-driven melanoma and lung cancer (33% ORR); initial data expected in the first half of 2024Well-tolerated monotherapy backbone enables multiple development approaches, including the ongoing exarafenib combination arm in NRAS mutant melanoma; dose selection expected in the second half of 2023SAN FRANCISCO and SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a...

STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April 17, 2023 (GLOBE NEWSWIRE) — MapKure, LLC, SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with advanced or refractory solid tumors harboring MAPK pathway aberrations. The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida. “The promising data we are sharing at AACR demonstrate the value of our next-generation RAF dimer inhibitor, BGB-3245, as a monotherapy in patients with MAPK pathway-altered...

Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the treatment of B-cell malignancies Poster presentation highlights specificity and potency of NX-5948 and superior cellular activity of both NX-2127 and NX-5948 against BTKi resistance mutations compared to other published BTK degraders SAN FRANCISCO, April 17, 2023 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced presentations covering its targeted protein degradation programs, including the structural disclosure of NX-2127 and new preclinical data for NX-2127 and NX-5948, highlighting their superior activity against...

KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023 KIN-8741, a highly selective c-MET inhibitor designed to cover acquired resistance in non-small cell lung cancer and other advanced adult solid tumors, is expected to enter the clinic in the first half of 2024 Kinnate to evaluate strategic alternatives for its CDK12 program    ~$231 million of cash, cash equivalents and investments as of March 31, 2023 is anticipated to fund planned operations into early 2025 Kinnate to host virtual investor webcast today, April 17, 2023, at 5:30 pm ETSAN FRANCISCO and SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced the addition...